Circulating miRNAs Respond to Denosumab Treatment After 2 Years in Postmenopausal Women With Osteoporosis-the MiDeTe study.

Zora Messner,David Carro Vázquez,Judith Haschka,Johannes Grillari,Heinrich Resch,Christian Muschitz,Peter Pietschmann,Jochen Zwerina,Matthias Hackl,Roland Kocijan

The Journal of clinical endocrinology and metabolism（2023）

引用 3|浏览3

暂无评分

摘要

Two years of DMAB treatment resulted in upregulation of 7 miRNAs, 4 of which are mainly transcribed in monocytes, indicating a potential impact of DMAB on circulating osteoclast precursor cells. These changes were associated to BMD gain and BTM suppression and could therefore be useful for monitoring DMAB treatment response.

查看译文

关键词

anti-osteoporotic therapy,denosumab,miRNAs,osteoporosis,postmenopausal osteoporosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要